(225 days)
Not Found
Unknown
The summary describes image processing for bone suppression and tissue equalization, which could be implemented using AI/ML, but the document does not explicitly mention AI, ML, or related terms like neural networks. The performance studies and substantial equivalence analysis focus on image quality metrics and reader study results, not on the underlying algorithmic approach.
No.
A therapeutic device is used to treat or cure a disease. This device is an image post-processing application intended to aid in the detection of lung nodules, not to treat them.
Yes
The device is described as generating an enhanced image to improve visibility of lung parenchyma and potentially discern the presence or absence of nodules, which are diagnostic tasks. It also provides metrics like Sensitivity and Specificity, commonly associated with diagnostic performance evaluation.
Yes
The device is described as a "dedicated post-processing application" that operates on existing digital radiographic images. There is no mention of any associated hardware components being part of the device itself.
Based on the provided information, this device is NOT an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostics are medical devices intended for use in vitro for the examination of specimens, including blood, tissue, and urine, derived from the human body, solely or principally for the purpose of providing information concerning a physiological or pathological state, or concerning a congenital abnormality, or to determine the safety and compatibility with potential recipients, or to monitor therapeutic measures.
- SoftView's Function: SoftView is a software application that processes digital radiographic images of the chest. It does not analyze biological specimens from the human body.
- Intended Use: The intended use is to enhance existing radiographic images to improve the visibility of lung parenchyma and potentially facilitate the discernment of nodules. This is image processing and analysis, not in vitro testing of biological samples.
Therefore, SoftView falls under the category of medical imaging software or image processing software, not an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
SoftView is intended to generate a bone-suppressed image from a original PA/AP chest radiograph.
SoftView is intended to generate an enhanced, secondary digital radiographic image of the chest. The enhanced AP or PA image of the chest provides improved visibility of the lung parenchyma through bone suppression and tissue equalization, and may facilitate discerning the presence or absence of nodules. The SoftView image provides adjunctive information and is not a substitute for the original PA/AP image. This device is intended to be used by trained professionals, such as physicians, radiologists, and technicians on patients with risk of having lung nodules and is not intended to be used on pediatric patients.
Product codes (comma separated list FDA assigned to the subject device)
LLZ
Device Description
SoftView is a dedicated post-processing application which suppresses bone structures from digital radiographic image of the chest.
Mentions image processing
Yes
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
digital radiographic image of the chest, original PA/AP chest radiograph, standard chest X-ray
Anatomical Site
Chest, lung parenchyma
Indicated Patient Age Range
Not intended to be used on pediatric patients.
Intended User / Care Setting
trained professionals, such as physicians, radiologists, and technicians
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Reader Study Results: A reader study was conducted to assess the benefit of SoftView to a radiologist for detecting actionable lung nodules. Reader performance was quantified by the area under the Localization Receiver-Operating Characteristic (LROC), curve which measures the conjoint ability to detect and correctly localize a true positive location on the radiograph. The difference in the average area under the LROC curve with and without the aid of SoftView was used to assess performance. The mean difference in the area under the curves was -0.098 (95% CI: -0.116 to -0.080), a statistically significant improvement. Sensitivity was 49.5% (95% CI: 45.9-53.0) without SoftView and 66.3% (95% CI: 63.1-69.7) with the addition of the SoftView image. Specificity was 96.1% (95% CI: 95.0-97.1) with the standard image and 91.8% (95% CI: 89.5-93.5) with the SoftView image.
Substantial Equivalence: To establish substantial equivalence, a comparative analysis of the contrast-to-noise ratio (CNR) of the residual bone in the predicate device's soft tissue images versus the subject device was performed. A CNR analysis was performed for both the GE and Fuji dual energy subtraction (DES) soft tissue images.
Analysis of scatter plots of the contrast-to-noise ratio (CNR) for the residual rib objects for an independent dataset was used to compare the SoftView correlative relationship relative to DES. Statistical hypothesis tests were also performed on the independent dataset. Two series of tests were performed, equivalency and non-inferiority tests. Data were stratified across modality, CR (Fuji DES), DR (GE DES), and lung regions, i.e., pleural, mid-lung, and hilum.
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Reader Study Results: A reader study was conducted to assess the benefit of SoftView to a radiologist for detecting actionable lung nodules. Reader performance was quantified by the area under the Localization Receiver-Operating Characteristic (LROC), curve which measures the conjoint ability to detect and correctly localize a true positive location on the radiograph. The difference in the average area under the LROC curve with and without the aid of SoftView was used to assess performance. The mean difference in the area under the curves was -0.098 (95% CI: -0.116 to -0.080), a statistically significant improvement. Sensitivity was 49.5% (95% CI: 45.9-53.0) without SoftView and 66.3% (95% CI: 63.1-69.7) with the addition of the SoftView image. Specificity was 96.1% (95% CI: 95.0-97.1) with the standard image and 91.8% (95% CI: 89.5-93.5) with the SoftView image.
Substantial Equivalence: To establish substantial equivalence, a comparative analysis of the contrast-to-noise ratio (CNR) of the residual bone in the predicate device's soft tissue images versus the subject device was performed. A CNR analysis was performed for both the GE and Fuji dual energy subtraction (DES) soft tissue images.
For the indicated strata of the data, it was demonstrated that SoftView is equivalent to the DES soft tissue images. The exception was the middle area of the lung for the DR modality (GE DES). SoftView was found to be better in this region based on an "ideal" CNR of the residual ribs in the soft tissue image being 0.0. Furthermore, a non-inferiority test demonstrated that SoftView was non-inferior to the DR and CR dual energy devices soft tissue images across all strata. Descriptive statistics of the means and standard deviations of the CNRs across the different modalities and regions of the lungs were in agreement.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Sensitivity was 49.5% (95% CI: 45.9-53.0) without SoftView and 66.3% (95% CI: 63.1-69.7) with the addition of the SoftView image. Specificity was 96.1% (95% CI: 95.0-97.1) with the standard image and 91.8% (95% CI: 89.5-93.5) with the SoftView image.
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 892.2050 Medical image management and processing system.
(a)
Identification. A medical image management and processing system is a device that provides one or more capabilities relating to the review and digital processing of medical images for the purposes of interpretation by a trained practitioner of disease detection, diagnosis, or patient management. The software components may provide advanced or complex image processing functions for image manipulation, enhancement, or quantification that are intended for use in the interpretation and analysis of medical images. Advanced image manipulation functions may include image segmentation, multimodality image registration, or 3D visualization. Complex quantitative functions may include semi-automated measurements or time-series measurements.(b)
Classification. Class II (special controls; voluntary standards—Digital Imaging and Communications in Medicine (DICOM) Std., Joint Photographic Experts Group (JPEG) Std., Society of Motion Picture and Television Engineers (SMPTE) Test Pattern).
0
KOS2363
Traditional 510(k) Premarket Notification SoftView™
Riverain Medical
510(K) SUMMARY
| Submission Date: | August 4, 2009 | MAR 1 8 2010 |
|---|---|---|
| Submitter Information: | ||
| Company Name: | Riverain Medical Group, LLC. | |
| Company Address: | 3020 South Tech Blvd., Miamisburg, OH 45342-4860 | |
| Contact Person: | Jennifer Vetter | |
| Director, Regulatory Affairs and Quality Assurance | ||
| Riverain Medical | ||
| 800.990.3387 | ||
| 937.425.6493 | ||
| jvetter@riverainmedical.com | ||
| Device Information: | ||
| Trade Name: | SoftView™ | |
| Regulation Number: | 21 CFR §892.2050 | |
| Regulation Name: | System, Image Processing, Radiological | |
| Regulatory Class: | Class II | |
| Product Code: | LLZ | |
| Predicate Device: | ||
| Dual Energy and Tissue Equalization Software Options | ||
| (K013481) | ||
| GE Medical Systems | ||
| Class II | ||
| Device Description: | SoftView is a dedicated post-processing application which | |
| suppresses bone structures from digital radiographic image | ||
| of the chest. | ||
| Intended Use: | SoftView is intended to generate a bone-suppressed image | |
| from a original PA/AP chest radiograph. | ||
| Indications for Use: | SoftView is intended to generate an enhanced, secondary | |
| digital radiographic image of the chest. The enhanced AP | ||
| or PA image of the chest provides improved visibility of | ||
| the lung parenchyma through bone suppression and tissue |
1
equalization, and may facilitate discerning the presence or absence of nodules. The SoftView image provides adjunctive information and is not a substitute for the original PA/AP image. This device is intended to be used by trained professionals, such as physicians, radiologists, and technicians on patients with risk of having lung nodules and is not intended to be used on pediatric patients.
Comparison to Predicate Device:
SoftView is substantially equivalent to the cited predicate device. Differences in the design and performance from the cited predicate device do not affect either the safety or effectiveness of SoftView for its intended use.
Conclusion:
SoftView is a mathematical model of a DES system that operates on a standard chest X-ray. It is an accurate representation of the soft tissue image produced by the predicate device's hardware/software process. The model is built from DES data by using simple image features extracted from the standard PA, along with target values derived from a DES soft tissue image. Thus, although SoftView does not generate the soft tissue image based on two exposures to the patient in real time, it is an accurate mathematical model of the process. The result of SoftView processing is a soft tissue image of the patient, consistent with that produced by a DES device but without requiring any additional radiation dose to the patient. Effectiveness of this model was demonstrated both by a reader study and by a comparative analysis of the contrast-to-noise ratio (CNR) of the residual bone in the predicate device's images in the soft tissue rib and clavicle regions, relative to the subject device.
Reader Study Results: A reader study was conducted to assess the benefit of SoftView to a radiologist for detecting actionable lung nodules. Reader performance was quantified by the area under the Localization Receiver-Operating Characteristic (LROC), curve which measures the conjoint ability to detect and correctly localize a true positive location on the radiograph. The difference in the average area under the LROC curve with and without the aid of SoftView was used to assess performance. The mean difference in the area under the curves was -0.098 (95% CI: -0.116 to -0.080), a statistically significant improvement. Sensitivity was 49.5% (95% CI:
2
Riverain Medical
Traditional 510(k) Premarket Notification SoftViewTM
45.9-53.0) without SoftView and 66.3% (95% CI: 63.1-69.7) with the addition of the SoftView image. Specificity was 96.1% (95% CI: 95.0-97.1) with the standard image and 91.8% (95% CI: 89.5-93.5) with the SoftView image.
Substantial Equivalence: To establish substantial equivalence, a comparative analysis of the contrast-to-noise ratio (CNR) of the residual bone in the predicate device's soft tissue images versus the subject device was performed. A CNR analysis was performed for both the GE and Fuji dual energy subtraction (DES) soft tissue images.
Analysis of scatter plots of the contrast-to-noise ratio (CNR) for the residual rib objects for an independent dataset was used to compare the SoftView correlative relationship relative to DES. Statistical hypothesis tests were also performed on the independent dataset. Two series of tests were performed, equivalency and non-inferiority tests. Data were stratified across modality, CR (Fuji DES), DR (GE DES), and lung regions, i.e., pleural, mid-lung, and hilum.
For the indicated strata of the data, it was demonstrated that SoftView is equivalent to the DES soft tissue images. The exception was the middle area of the lung for the DR modality (GE DES). SoftView was found to be better in this region based on an "ideal" CNR of the residual ribs in the soft tissue image being 0.0. Furthermore, a non-inferiority test demonstrated that SoftView was non-inferior to the DR and CR dual energy devices soft tissue images across all strata. Descriptive statistics of the means and standard deviations of the CNRs across the different modalities and regions of the lungs were in agreement.
3
Image /page/3/Picture/0 description: The image shows the seal of the Department of Health & Human Services-USA. The seal is circular and contains an abstract image of an eagle. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES-USA" is arranged around the top half of the circle.
DEPARTMENT OF HEALTH & HUMAN SERVICES
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Room - WO66-G609 Silver Spring. MD 20993-0002
MAR 1 8 2010
Ms. Jennifer Vetter Director-Regulatory and Quality Assurance Riverain Medical Group, LLC 3020 South Tech Blvd. MIAMISBURG OH 45342
Re: K092363
Trade/Device Name: Softview™M Regulation Number: 21 CFR 892.2050 Regulation Name: Picture archiving and communications system Regulatory Class: II Product Code: LLZ Dated: February 5, 2010 Received: February 12, 2010
Dear Ms. Vetter:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of
4
medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office
of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely vours.
Donald J. Trump
Donald J. St.Pierre Acting Director Division of Radiological Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
5
2.0 INDICATIONS FOR USE STATEMENT
510(k) Number (if known): K
Device Name:
SoftView™
Indications for Use:
SoftView is intended to generate an enhanced, secondary digital radiographic image of the chest. The enhanced AP or PA image of the chest provides improved visibility of the lung parenchyma through bone suppression and tissue equalization, and may facilitate discerning the presence or absence of nodules. The SoftView image provides adjunctive information and is not a substitute for the original PA/AP image. This device is intended to be used by trained professionals, such as physicians, radiologists, and technicians on patients with risk of having lung nodules and is not intended to be used on pediatric patients.
Prescription Use X (Part 21 CFR 801 Subpart D)
AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE OF NEEDED)
| Concurrence of CDRH, Office of Device Evaluation (ODE) | ||
|---|---|---|
(Division Sign-Off)
Page 1 of 1
Division Sign Off)
Division of Radiological Devices
Office of In Vitro Diagnostic Device Evaluation and Safety
510K K092363